The future perspectives for care for patients with high Lp(a)
May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
Elevated Lp(a) levels are prevalent and associated with elevated CV risk 0:01
Elevated Lp(a) levels may be implicated in those with unexplained CV risk 1:28
What is needed to improve care for individuals with high Lp(a) levels? 3:09
Proposed underlying pathogenic pathways of Lp(a)'s atherogenicity 3:46
Identifying subjects and high-risk families 5:40
Therapeutic options to lower Lp(a) 7:01
Faculty & Disclosures
Prof. Erik Stroes MD PhD – is Chairman, Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
Funding
The PACE foundation received funding for this session via an unrestricted educational grant from Amgen